It's difficult not to be excited by the potential of breath-activated cancer diagnosis as published widely in the UK media this week.
For anyone that is going through or has been through the cancer diagnosis process, it seems that time stands still while some of the most critical life-changing diagnoses come crashing down around you.
At the point of cancer confirmation, the 'mortality fairy' bashes us hard. It hit my family hard in the last month.
But it got me thinking, what if those life changing conversations are more about indicators of disease, outcome-driven treatment and success rates. How are those conversations really shaping our approach to treatment? And how do we help all stakeholders better communicate risk benefit better?
Breath activation technology may speed up diagnosis and provide a degree of certainty on the disease trajectory. Evidence of improved outcomes will show how technology supports better health
Researchers have identified the lung cancer biomarker, a molecule called butylated hydroxytoluene, which gives the Ancon Medical NBT device the capability now to screen for the disease